Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.
暂无分享,去创建一个
D. Cooper | A. Kelleher | J. Zaunders | M. Law | A. Carr | G R Kaufmann | P Cunningham | A D Kelleher | J Zaunders | A Carr | J Vizzard | M Law | D A Cooper | G. Kaufmann | J. Vizzard | P. Cunningham
[1] J. Mellors,et al. Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.
[2] L M Wahl,et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection , 1997, Journal of virology.
[3] Xiping Wei,et al. Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.
[4] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[5] D. Ho,et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.
[6] A. Fauci,et al. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] Martin A. Nowak,et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections , 1995, Nature.
[8] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[9] Lawrence Corey,et al. Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.
[10] A. Gerber,et al. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections , 1994 .
[11] P. Klenerman,et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[12] D. Hawkins,et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. , 1995, The New England journal of medicine.
[13] M. Nowak,et al. Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.